anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients assigned to tirzepatide will undergo dose titration starting with 2.5 mg per day with an increase every four weeks if tolerated by nausea. During the first 6 weeks, weight loss must be matched with the dietary weight loss arm at 0.6 kg/week. Participants will be seen every two weeks to review diet and physical activity, evaluate tolerability/side effects, and obtain morning weight. If weight loss is greater than 0.6 kg/week, recommendations to increase caloric intake will be made through the week 6 visits that repeat baseline testings (biopsy, metabolic tests, and regional fat scans). After the 6th week, weight loss can occur naturally without any restrictions (no further matching to the dietary weight loss group is required). Starting at week 8 the visits are decreased to every 4 weeks. Biopsies, metabolic tests, and regional fat scans are completed at baseline, week 6, and end of study (week 22).
The invention discloses polyphenol flavonoid shown in the formula (I) and a preparing method and application of the polyphenol flavonoid. In the formula (I), R1 and R3 can be one of H or OH at the same time. At least one of R2, R4 and R5 is glycosyl, and the rest of R2, R4 and R5 are H or OH. The glycosyl kinds include glucose, galactose, mannose and rhamnose and the glucose, the galactose and the mannose and rhamnose can be connected to form bioside or trioside. The polyphenol flavonoid is of a polyphenol structure and is extracted from castanea mollissima involucre, castanea mollissima flowers, castanea mollissima shells and castanea mollissima cores and has the good activity for resisting the human lung cancer, the human liver cancer, the human pancreatic cancer, the human stomach cancer and the human colon cancer. The polyphenol flavonoid can be combined with acceptable carriers on pharmacy to prepare clinically acceptable medicine, and the polyphenol flavonoid is used for treating tumors.
PURPOSE: A pharmaceutical composition and a functional food is provided to have actions of alcohol absorption suppression, alcoholic cirrhosis suppression, and/or hangover relief without influencing physiological function of other organs. CONSTITUTION: A functional food comprises: a green tea extract containing catechingallate, poly-gamma-glutamic acid, and a carrier which is acceptable pharmaceutically. The poly-gamma-glutamic acid has a molecular weight of 1-4000 kDa. The poly-gamma-glutamic acid has an action of suppressing catechingallate absorption. A composition for hangover relief comprises: poly-gamma-glutamic acid and a green tea extract containing catechingallate. A food for hangover relief comprises: poly-gamma-glutamic acid and a green tea extract containing catechingallate.
A computing system for determining a systematic training strategy for the user is provided. The computing system includes a user device that uses one or more sensors to obtain partial pressure of oxygen (PO2) levels of a user over a period of time. The user device provides previous PO2 levels to a personalized erythropoiesis model generation computing platform. The computing platform obtains individualized user data for the user indicating or more previous hematocrit and/or hemoglobin measurements for the user. The computing platform determines an individualized erythropoiesis model for the user based on the one or more previous hematocrit and/or hemoglobin measurements and the previous PO2 information, and employs the individualized erythropoiesis model to determine predicted hematocrit and/or hemoglobin measurements. The computing platform performs one or more actions based on the one or more predicted hematocrit and/or hemoglobin measurements.
There is a different aspect of reactogenicity between BNT162b2 and ChAdOx1 nCoV-19 vaccine. Both new platform vaccines were concerned if they would elicit more significant local or systemic reactogenicity compared to the conventional vaccines. Previous studies had reported that immune cells such as mast cells and macrophages are activated just after vaccination, and release proinflammatory cytokines such as interleukin (IL)-6 and tumor necrosis factor (TNF)-α. The post-vaccination kinetics of inflammatory cytokines would be variable by each vaccine platform, and might be associated with reactogenicity. It is an interesting issue to be investigated whether the reactogenicity following newly developed BNT162b2 and ChAdOx1 would be associated with immunogenicity and inflammatory response or not. To better clarify these uncertainties, we evaluated the change of antibody response between BNT162b2 and ChAdOx1 over three months post-vaccination, in relation to the kinetics of inflammatory cytokines and reactogenicity.
Constitute with 60 mL of water and replace cap. Shake bottle well before dispensing. Do not refrigerate. Constituted suspension should be consumed within 12 hours. 

For pediatric dosing in patients weighing less than 75 lb (34 kg), use of a dosing device is recommended. The pharmacist should inform the patient's caregiver that any suspension remaining after dosing MUST be discarded.
Fenofibrate tablets, USP is a lipid regulating agent available as tablets for oral administration. Each tablet contains 160 mg of fenofibrate, USP. The chemical name for fenofibrate is 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester with the following molecular structure:

The molecular formula is C20H21O4Cl and the molecular weight is 360.83; fenofibrate, USP is very soluble in methylene chloride, slightly soluble in alcohal and prectically insoluble in water. The melting point is 79 - 82° C. Fenofibrate, USP is a white or almost white crystalline powder.

Inactive Ingredients: Each tablet contains colloidal silicon dioxide, crospovidone, lecithin (soya), microcrystalline cellulose, polyvinyl alcohol, povidone, pregelatinized starch, sodium lauryl sulfate, sodium stearyl fumarate, talc, titanium dioxide and xanthan gum.

Meets USP Dissolution Test 2.
The investigators have completed the construction of the eye-tracking diagnostic and warning system and have piloted the new system. The plan is to recruit 1,000 individuals at Clinical High Risk for Psychosis (CHR) for model validation of predictive outcomes, and 1,000 patients with common mental disorders for model validation of diagnostic classification. This cohort includes 300 patients with schizophrenia, 300 patients with affective disorders, 200 patients with anxiety disorders, and 200 patients with cognitive impairment in the elderly. The system will also directly connect with the investigators' previous research data collection system and be deployed in no fewer than one hospital's healthcare system. Additionally, variables that may affect the accuracy of results will be fine-tuned to ensure that the eye-tracking and fundus system more accurately reflects actual clinical conditions. The application of the system will revolve around a big data analysis platform and seamlessly integrate with the existing hospital information systems, designing real-time feedback report modules to assist clinicians in making objective diagnoses efficiently and effectively.
Diabetic nephropathy is one of the most important causes of end stage renal disease in the world. Recently In a multicenter, randomized clinical trial performed in China, which aimed to evaluate the efficacy and safety of compound α-keto acid tablet in combination with low protein diet (LPD+KA) in delaying the progress of type 2 diabetic nephropathy(T2DN). In that study it was found that LPD+KA was associated with amelioration of proteinuria, better reduction in the loss of kidney function compared with LPD alone meanwhile nutrition status remained well in both group(Role of Ketoanalogs in diabetic nephropathy-China study, to be submitted for publication). However, in that study the mechanisms underlined these effects were not been elucidated This research proposal is a part of the continuation of that study. Restriction of Protein intake, strictly control blood pressure, particularly using renin-angiotensin system (RAS) blockade have been shown to ameliorate proteinuria and progression of CKD. Podocyte damage has been know to play critical role for proteinuria and renal function loss A recent study showed that the mRNA expression of podocyte markers in urinary sediment is increased in patients with T2DN, and this effect can be inhibited by ACE inhibitor and ARB, which indicates the important role of local renal RAS to involve in the damage. Urinary angiotensinogen level is a good marker of the situation of renal RAS. Consequently the investigators are proposing to study the effect of LPD+KA on podocyte as well as on local RAS in the kidney.
Predicting postpartum hemorrhage (PPH) before delivery is crucial for enhancing patient outcomes, enabling timely transfer and implementation of prophylactic therapies. We attempted to utilize machine learning (ML) using basic pre-labor clinical data and laboratory measurements to predict postpartum Hemoglobin (Hb) in non-complicated singleton pregnancies. The local databases of two academic care centers on patient delivery were incorporated into the current study. Patients with preexisting coagulopathy, traumatic cases, and allogenic blood transfusion were excluded from all analyses. The association of pre-delivery variables with 24-h post-delivery hemoglobin level was evaluated using feature selection with Elastic Net regression and Random Forest algorithms. A suite of ML algorithms was employed to predict post-delivery Hb levels. Out of 2051 pregnant women, 1974 were included in the final analysis. After data pre-processing and redundant variable removal, the top predictors selected via feature selection for predicting post-delivery Hb were parity (B: 0.09 [0.05-0.12]), gestational age, pre-delivery hemoglobin (B:0.83 [0.80-0.85]) and fibrinogen levels (B:0.01 [0.01-0.01]), and pre-labor platelet count (B*1000: 0.77 [0.30-1.23]). Among the trained algorithms, artificial neural network provided the most accurate model (Root mean squared error: 0.62), which was subsequently deployed as a web-based calculator: https://predictivecalculators.shinyapps.io/ANN-HB . The current study shows that ML models could be utilized as accurate predictors of indirect measures of PPH and can be readily incorporated into healthcare systems. Further studies with heterogenous population-based samples may further improve the generalizability of these models.
The opioid blockade study assessed the blockade of subjective opioid effects, PK, and safety of BRIXADI weekly in 47 patients with moderate or severe opioid use disorder. Forty-six patients completed the study. Subjects were randomized to receive two injections of BRIXADI (weekly) once weekly for 2 weeks either at a 24 mg or 32 mg dose level.

After stabilization on immediate-release morphine, all patients completed a 3-day qualification/baseline hydromorphone (HM) challenge session, which included intramuscular administration of 3 doses of HM (0 mg [placebo], 6 mg and 18 mg) once daily for 3 consecutive days. Patients were not exposed to buprenorphine during the baseline/qualification phase.

Following the qualification phase, eligible patients were randomly assigned to receive 2 doses of either 24 mg (22 patients) or 32 mg (24 patients) BRIXADI (weekly) with each dose administered one week apart. Two HM challenge sessions (Days 1-3 and 4-6 for the first session and Days 8-10 and 11-13 for the second session, respectively) were conducted after each dose of BRIXADI (weekly).

The primary endpoint was the peak effect (Emax) on a 100-mm bipolar (i.e., 50=neutral response) "Drug Liking" Visual Analog Scale (VAS). The pre-defined upper bound of the 95% CI for complete blockade of drug liking was an 11 mm difference between VAS Emax scores obtained for HM doses compared with placebo.

During the qualification/baseline phase, mean Emax scores for placebo were neutral while intramuscular hydromorphone 6 and 18 mg produced dose-related increases in the scores. Beginning with the first injection of BRIXADI (weekly) 24 mg or 32 mg weekly, no active intramuscular hydromorphone dose resulted in a mean drug liking VAS Emax score of 11 mm or greater when compared to placebo, which demonstrated complete blockade that was sustained throughout the first and second dosing intervals (see Figure 15). Individual subject scores are shown in Figure 16.

Figure 15: Mean Difference in Placebo-Corrected Peak Drug Liking

Figure 16: Mean Difference in Placebo-Corrected Peak Drug Liking with Individual Scores
A mixed liposome pharmaceutical formulation with multilamellar vesicles.  The formulation comprises a proteinic pharmaceutical agent, water, an alkali metal C8 to C22 alkyl sulphate in a concentration of from 1 to 10 wt./wt.% of the total formulation, at least one membrane-mimetic amphiphile and at least one phospholipid. The membrane mimectic is hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, lauramidopropyl betain, lauramide monoisopropanolamide, sodium cocoamphopropionate, bishydroxypropyl dihydroxypropyl stearammonium chloride, polyoxyethylene dihydroxypropyl stearammonium chloride, dioctadecyldimethylammonium chloride, sulphosuccinates, stearamide DEA, gamma-linoleic acid, borage oil, evening primrose oil, monoolein, sodium tauro dihydro fusidate, fusidic acid, alkali metal isostearyl lactylates, alkaline earth metal isostearyl lactylates, panthenyl triacetate, cocamidopropyl phosphatidyl PG-diammonium chloride, stearamidopropyl phosphatidyl PG-diammonium chloride, borage amidopropyl phosphatidyl PG-diammonium chloride, borage amidopropyl phosphatidylcholine, polysiloxy pyrrolidone linoleyl phospholipid, trihydroxy-oxo-cholanylglycine and alkali metal salts thereof, and octylphenoxypolythoxyethanol, polydecanol X-lauryl ether, polydecanol X-oleyl ether, wherein X is 9 to 20, or combinations thereof. The phospholipid is phospholipid GLA, phosphatidyl serine, phosphatidylethanolamine, inositolphosphatides, dioleoylphosphatidylethanolamine, sphingomyelin, ceramides, cephalin, triolein, lecithin, saturated lecithin and lysolecithin, and combinations thereof. The amount of each membrane mimetic amphiphile and phospholipid is present in a concentration of from 1 to 10 wt./wt.% of the total formulation, and the total concentration of membrane mimetic amphiphiles and phospholipids is less than 50 wt./wt.% of the formulation. Also described is a pressurised container containing a propellant that is liquid under pressure, the formulation described above, and a phenolic compound selected from phenol and methyl phenol in a concentration of from 1 to 10 wt./wt.% of the formulation. Also described is the use of the pharmaceutical agent for the administration of an aerosol pharmaceutical formulation by spraying a predetermined amount of a mixture of propellant (particularly into the buccal cavity of a human) and an intermediate formulation which comprises the formulation described above and a phenolic compound selected from phenol and methyl phenol in a concentration of from 1 to 10 wt./wt.% of the formulation.
Subjects will serve as their own control in this single-arm protocol. All subjects will receive 400 IU/day of vitamin D as the intervention. Comparisons will be made between Caucasian and Hispanic infants.
Each family will receive a randomized packet containing educational information, rewards charts and an adult literacy test. The treatment plan will be determined based on recommendations from the clinical guidelines for the Evaluation and Treatment of Functional Constipation Infants and Children as published by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. At the first visit, the parent(s) will complete an adult literacy test and an initial paper questionnaire regarding symptoms, adherence to the treatment plan and demographics. At 1 month, the primary investigator will call each family and administer a phone survey regarding symptoms and adherence to the treatment plan in the past month. At 3 months, the families will return for a follow up visit with their 3 month reward charts and complete a final paper survey regarding the child's symptoms and adherence to the treatment plan.
Participants randomly assigned to this group will be instructed to measure their BP for seven consecutive days once each month during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
Liposomes containing lipophilic active ingredient are produced by dehydrating a mixture of liposomes, lipophilic active ingredient and sugar, usually followed by a rehydration step to form dehydration-rehydration vesicles. The lipophilic drug is suitably paclitaxel. The sugar is usually sucrose. The liposome forming compounds preferably include cholesterol and phosphatidyl-choline, and optionally an anionic lipid. The ratio of sugar:lipid is preferably at least 5:1 w/w. The ratio of lipid:drug is preferably (up to 10):1 w/w.
Patients undergo whole-pelvic radiotherapy (WPRT)\* (3D-CRT or IMRT) once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo brachytherapy as in arm I.
PURPOSE: A viroplex for cell transfection of target nucleotides and a gene delivery method using the same are provided to induce effective adhesion with suspension cells. CONSTITUTION: A viroplex for transfection to target nucleotides comprises a target nucleotide sequence, cationic lipid, and viral agent. The target nucleotide is a recombinant DNA, pDNA(plasmid DNA), siRNA(small interfering RNA) or miRNA. The cationic lipid is polyvalent cationic lipid. The viral agent is enveloped virus coat component, sendai virus-derived F/HN(fusion/hemagglutinin-neuraminidase) protein. A gene delivery method comprises a step of contacting the viroplex with cells.
Asthma is a chronic airway inflammatory disease. The excessive proliferation of airway smooth muscle cells (ASMCs) is associated with airway remodeling. Ze-Qi-Tang (ZQT) is a popular traditional Chinese medicine preparation and has been confirmed to have therapeutic effects on lung diseases. This study is aimed to probe the biological function of ZQT in asthma. RT-qPCR and ELISA were utilized for testing the mRNA levels and concentrations of pro-inflammatory factors. Colony formation and transwell assay were applied to test cell viability and migration. The mouse model with asthma was established by ovalbumin (OVA) induction. Western blot was utilized for detecting the activation of PI3K/AKT/NF-κB pathway. We found that the concentrations of proinflammatory factors in cells induced by PDGF-BB could been suppressed by ZQT. ZQT-H treatment notably repressed cell viability and proliferation. Furthermore, we proved the suppressive effect of ZQT on airway inflammation in asthma mice. Additionally, we discovered that ZQT could suppress the PI3K/AKT/NF-κB pathway in PDGF-BB-induced ASMCs. To sum up, ZQT reduced airway inflammation and remodeling in mice with asthma via inactivating PI3K/AKT/NF-κB pathway.
All participants will receive a single dose of tocilizumab intravenously. An additional dose of tocilizumab may be instituted as premedication for subsequent Cycle 1 dose(s) of cevostamab and Cycle 1 cevostamab doses for other treatment arms.
This site will serve as the control site and will receive lactated Ringer's (saline solution) (2 µl/min) throughout the entire duration of the protocol. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
Frequency of aerobic/resistance training in older women

Abstract Combined aerobic and resistance training have unique benefits for maintaining a physical activity (PA). However, the optimal training program for combining these two modes of training in older adults is unknown. This study builds on current and past studies showing that training induced gains in aerobic fitness, muscle strength, and ease of PA are important for maintaining an active lifestyle, a favorable body composition, and high bone density. Traditionally 3 d/wk combined training has been felt to be optimal while recent studies suggest 1 d/wk combined training may create similar adaptations as more frequent training. However, our previous and ongoing studies suggest that 1 d/wk combined aerobic and resistance training (C1) may be insufficient stimulus to induce optimal adaptations and that 3 d/wk combined training (C3) may be too frequent a stimulus for older adults. This study will enable us to compare the effects of C1, 2 d/wk combined training (C2), and C3 on fitness, body composition, ease of PA, PA, and total free-living energy expenditure (TEE). We hypothesize that C2 will result in a larger increase in muscle size, bone density, strength, aerobic capacity, power, ease of PA, PA, and TEE than either C1 or C3. Circulating cytokines and psychological mood states linked to chronic overstress will also be examined. Objectives: We will examine changes in circulating cytokines, mood states, muscle size, bone density, aerobic capacity, strength, power, ease of PA, PA, and TEE following 16 and 32 wks training. Design: We will to evaluate 78 (\>60 yrs) Black and White women matched for age, race, and BMI into C1, C2, or C3 groups prior to, after 16, and after 32 wks training. Women will undergo evaluation of metabolic parameters in a General Clinical Research Center. Significance: This study should provide insight into the effects combined training frequency has on improving fitness, ease of PA, and maintenance of a high TEE. Such information is critical to our understanding of ways to improve well being, quality of life, and independence of an aging population.
The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain lasting twenty minutes. The field and timing parameters of the LFMS pulses, such as pulse timing, duration, frequency, and electric and magnetic field distribution and direction are different from other neurostimulation methods. LFMS electromagnetic fields are significantly weaker than those occurring in electroconvulsive therapy (ECT) and repeated transcranial magnetic stimulation (rTMS).

LFMS was discovered at McLean Hospital and has been studied as an experimental antidepressant treatment at McLean. Results from the investigator's single-visit protocol (2006-P-001655) are encouraging, and demonstrate an immediate mood improvement from LFMS in depressed subjects. This indicates that LFMS continues to show potential as a treatment for depression. The profile of clinical response to LFMS that was observed in that study included improvement in symptoms of anxiety. In this current proposal the investigator's will study the effects of LFMS on these symptoms of depression and anxiety that are present in a population with a primary diagnosis of PTSD. The proposed protocol involves three treatments on consecutive days with follow-up ratings one week after the first treatment and follow-up by phone ratings in weeks three and four after the first treatment.